As an inhibitor of HDAC1 and HDAC2, SAHA, also known as Vorinostat, has a broad spectrum of epigenetic activities through the inhibition of histone acetylation and has been used to treat several diseases including glioblastoma [47] and non-small-cell lung carcinoma [48]. Here, HDAC1 is linked to non-small cell lung carcinoma.